

NASDAQ: IDYA
May 2026

Improving Lives Through Transformative Precision Medicines



IDEAYA Highlights

Breakthrough Science on transformative programs in precision medicine, including Synthetic Lethality – an emerging area of precision medicine

Broad Pipeline of potential *first-in-class* precision medicine oncology programs with defined patient biomarkers

Proven Management Team with deep business and scientific experience has built leading oncology companies

Pharma Strategic Partnerships include combinations with Pfizer¹ and Gilead¹, and licensing agreements with Hengrui², and Servier³

Strong Balance Sheet of ~\$973 million⁴ with capital efficient model

Analyst Coverage by BTIG, Cantor, Citi, Citizens JMP, Goldman Sachs, Guggenheim, Jefferies, JP Morgan, Leerink, LifeSci Capital, Mizuho Securities, Oppenheimer, RBC, Stephens, TD Securities, Truist Securities, UBS, Wedbush, and Wells Fargo

- (1) Clinical Trial Collaboration and Supply Agreements, independently with Pfizer (Darovasertib + Crizotinib), and Gilead (IDE397 + Trodelvy®); IDEAYA retains all commercial rights to its products
- (2) IDE849 (SHR-4849): DLL3 Top1i Antibody Drug Conjugate. Exclusive license agreement with Jiangsu Hengrui Pharmaceuticals Co., Ltd for worldwide rights outside of Greater China
- (3) Servier exclusive license agreement for darovasertib. IDEAYA retains all US commercial rights and is eligible to receive \$320 million in regulatory and commercial milestones, clinical development cost share, plus double-digit royalties on net sales
- (4) Includes aggregate of approximately \$972.9 million of cash, cash equivalents and marketable securities as of Mar 31, 2026, as detailed on IDEAYA's Form 10-Q filed with the U.S. SEC; runway projections based on current operating plan

IDEAYA Biosciences – Fact Sheet

Founded 2015 on the thesis that Synthetic Lethality would emerge as a central focus of precision medicine oncology, with significant Pharma interest and the potential to develop *first-in-class* therapeutics for biomarker-defined cancer patient populations.

Broad Pipeline of clinical and preclinical precision medicine oncology programs with defined patient biomarkers, including

- *Darovasertib (IDE196)* targeting PKC in combination with crizotinib, a cMET inhibitor, for metastatic uveal melanoma (MUM) and metastatic cutaneous melanoma, and as monotherapy for neoadjuvant and adjuvant uveal melanoma (UM),
- *IDE397* targeting MAT2A for patients having tumors with MTAP deletion, a population estimated to represent ~15% of all solid tumors,
- *IDE849* targeting DLL3 for patients having small cell lung cancer and neuroendocrine tumors,
- *IDE275* for patients having tumors with high microsatellite instability,
- *IDE161* targeting PARG for patients having solid tumors with HRD and endometrial cancer,
- *IDE705* for patients with tumors having mutations in BRCA or other homologous recombination deficiency (HRD),
- *IDE892* targeting PRMT5 for patients having tumors with MTAP deletion and enabling wholly-owned combination with *IDE397*,
- *IDE034* for patients with B7H3/PTK7 expression in solid tumors.
- *IDE574* targeting KAT6/7 in breast and NSCLC with 8p11 amplification, and in the setting of lineage addiction,
- *Next-Gen SL*, for undisclosed synthetic lethality targets for molecularly-defined patient populations.

Proven Management Team with deep business and scientific experience has built leading oncology biotech companies, led by CEO Yujiro S. Hata, M.B.A., an entrepreneur with over 20 years of experience building companies that have delivered innovative therapies to patients.

Scientific Advisory Board includes world-class scientists who are key opinion leaders in precision medicine oncology and synthetic lethality, including SAB Chair Frank McCormick, Ph.D. (UCSF), and Bill Sellers, M.D. (Broad Institute, Novartis).

Pharma Strategic Partnerships and Collaborations with Pfizer¹, Gilead¹, Hengrui², and Servier³.

Strong Balance Sheet of ~\$973 million⁴, with a capital efficient model, supporting clinical data milestones across multiple programs, including for darovasertib – targeting PKC in metastatic uveal melanoma (MUM), and neoadjuvant and adjuvant uveal melanoma (UM), *IDE397* – targeting MAT2A in MTAP-deletion tumors and *IDE849* – targeting DLL3 in small cell lung cancer and neuroendocrine tumors.

Analyst Coverage by BTIG, Cantor, Citi, Citizens JMP, Goldman Sachs, Guggenheim, Jefferies, JP Morgan, Leerink, LifeSci Capital, Mizuho Securities, Oppenheimer, RBC, Stephens, TD Securities, Truist Securities, UBS, Wedbush, and Wells Fargo.

(1) Clinical Trial Collaboration and Supply Agreements, independently with Pfizer (Darovasertib + Crizotinib), Gilead (*IDE397* + Trodelvy®), and Merck (*IDE161* + KEYTRUDA®); IDEAYA retains all commercial rights to its products

(2) *IDE849* (SHR-4849): DLL3 Top1 Antibody Drug Conjugate. Exclusive license agreement with Jiangsu Hengrui Pharmaceuticals Co., Ltd for worldwide rights outside of Greater China

(3) Servier exclusive license agreement for darovasertib. IDEAYA retains all US commercial rights and is eligible to receive \$320 million in regulatory and commercial milestones, clinical development cost share, plus double-digit royalties on net sales

(4) Includes aggregate of approximately \$972.9 million of cash, cash equivalents and marketable securities as of Mar 31, 2026, as detailed on IDEAYA's Form 10-Q filed with the U.S. SEC; runway projections based on current operating plan

